Reuters logo
BRIEF-Miragen Therapeutics announces new data from phase 1 clinical trial evaluating MRG-106
2017年6月5日 / 上午11点17分 / 4 个月前

BRIEF-Miragen Therapeutics announces new data from phase 1 clinical trial evaluating MRG-106

June 5 (Reuters) - Miragen Therapeutics Inc:

* Miragen Therapeutics presents new data from phase 1 clinical trial evaluating MRG-106 in subjects with Mycosis Fungoides

* MRG-106 has been generally well-tolerated to date

* Only one grade 3 adverse event, Pruritus (itchy skin), was considered potentially related to MRG-106 administration Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below